These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 9207934)

  • 1. Pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1 beta-converting enzyme inhibitor.
    Dolle RE; Prasad CV; Prouty CP; Salvino JM; Awad MM; Schmidt SJ; Hoyer D; Ross TM; Graybill TL; Speier GJ; Uhl J; Miller BE; Helaszek CT; Ator MA
    J Med Chem; 1997 Jun; 40(13):1941-6. PubMed ID: 9207934
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors.
    Wang Y; O'Neil SV; Wos JA; Oppong KA; Laufersweiler MC; Soper DL; Ellis CD; Baize MW; Fancher AN; Lu W; Suchanek MK; Wang RL; Schwecke WP; Cruze CA; Buchalova M; Belkin M; De B; Demuth TP
    Bioorg Med Chem; 2007 Feb; 15(3):1311-22. PubMed ID: 17127070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient stereoselective synthesis of [3S(1S,9S)]-3-[[[9-(benzoylamino) octahydro-6,10-dioxo-6H-pyridazino-(1,2-a)(1,2)-diazepin-1-yl]-carbonyl ]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor.
    Chen MH; Goel OP; Hyun JW; Magano J; Rubin JR
    Bioorg Med Chem Lett; 1999 Jun; 9(11):1587-92. PubMed ID: 10386941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total synthesis of the interleukin-1beta converting enzyme inhibitor EI-1941-2 using tandem oxa-electrocyclization/oxidation1.
    Kleinke AS; Li C; Rabasso N; Porco JA
    Org Lett; 2006 Jun; 8(13):2847-50. PubMed ID: 16774272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pralnacasan (vertex pharmaceuticals).
    Siegmund B; Zeitz M
    IDrugs; 2003 Feb; 6(2):154-8. PubMed ID: 12789619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
    Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
    J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
    Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
    Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 3-arylamino- and 3-cycloalkylamino-5, 6-diphenyl-pyridazines active as ACAT inhibitors.
    Toma L; Giovannoni MP; Vergelli C; Dal Piaz V; Kwon BM; Kim YK; Gelain A; Barlocco D
    Arch Pharm (Weinheim); 2002; 335(11-12):563-6. PubMed ID: 12596221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
    Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
    J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
    Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP
    Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
    J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design to enhance the penetration into the retina via ocular instillation.
    Shirasaki Y; Takahashi H; Yamaguchi M; Inoue J
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5174-7. PubMed ID: 18789863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
    Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
    Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide.
    Boileau C; Martel-Pelletier J; Moldovan F; Jouzeau JY; Netter P; Manning PT; Pelletier JP
    Arthritis Rheum; 2002 Oct; 46(10):2637-47. PubMed ID: 12384922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
    Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
    J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.